Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study - Scorecard - MDSpire

Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study

  • By

  • Marta Codirenzi

  • Federica Davanzo

  • Luca Iorio

  • Eleonora Fiorin

  • Gabriella Guarnieri

  • Fulvia Chieco Bianchi

  • Alessia Achille

  • Maria Rita Marchi

  • Andrea Vianello

  • Andrea Doria

  • Roberta Ramonda

  • Roberto Padoan

  • June 15, 2026

  • 0 min

Share

Clinical Scorecard: Real-World Assessment of Benralizumab Versus Two Mepolizumab Dosing Strategies in Eosinophilic Granulomatosis with Polyangiitis: A 24-Month Prospective Cohort Study at a Single Center

At a Glance

CategoryDetail
Condition
Key MechanismsAnti–IL-5 and anti–IL-5 receptor biologics targeting eosinophilic inflammation, specifically noting the differences in action between benralizumab and mepolizumab.
Target Population
Care Setting

Key Highlights

  • statistical_significance

Guideline-Based Recommendations

Diagnosis

    Management

    • E
    • x
    • p
    • a
    • n
    • d
    • o
    • n
    • m
    • a
    • n
    • a
    • g
    • e
    • m
    • e
    • n
    • t
    • s
    • t
    • r
    • a
    • t
    • e
    • g
    • i
    • e
    • s
    • f
    • o
    • r
    • n
    • o
    • n
    • -
    • s
    • e
    • v
    • e
    • r
    • e
    • E
    • G
    • P
    • A
    • ,
    • i
    • n
    • c
    • l
    • u
    • d
    • i
    • n
    • g
    • p
    • o
    • t
    • e
    • n
    • t
    • i
    • a
    • l
    • u
    • s
    • e
    • o
    • f
    • G
    • C
    • s
    • a
    • l
    • o
    • n
    • e
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Adults with EGPA treated with anti-IL-5/IL-5R biologics.

        Benralizumab and mepolizumab regimens showed effective and well-tolerated outcomes over 24 months.

        Clinical Best Practices

        • monitoring

        Related Resources & Content

        Original Source(s)

        Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study

        • by Marta Codirenzi, Federica Davanzo, Luca Iorio, Eleonora Fiorin, Gabriella Guarnieri, Fulvia Chieco Bianchi, Alessia Achille, Maria Rita Marchi, Andrea Vianello, Andrea Doria, Roberta Ramonda, Roberto Padoan

        • June 15, 2026

        Related Content

        Case Report: Paradoxical psoriasis under TNF-α blockade may represent generalized abscessing staphyloderma – GASD syndrome by TNF antagonists

        RA Genetics May Reveal Link to Gum Disease

        Analysis of East Asian genetic data found a modest inverse association between rheumatoid arthritis susceptibility and periodontitis risk, though researchers said the findings require confirmation in independent cohorts.

        Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives